Our Company
Presentation
Management Team
Board of directors
Scientific Advisory Board
Contact
Products
Tedopi®
OSE-279
Lusvertikimab (OSE-127)
Pegrizeprument (FR104)
BI 770371
ABBV-230
CLEC-1
Research & Development
Scientific publications
Investors
Press Releases
Regulated information
Financial documents
General Shareholders’ meetings
Partnerships
Pharma partnerships
Clinical partnerships
Academic and public Partnerships
News
Agenda
Press Releases
Letter to shareholders
Newsletter
Contact
en
fr
P
r
o
j
e
c
t
s
A
r
c
h
i
v
e
s
October 2021
First-half 2020 financial report
October 2021
2019 Universal registration document
October 2021
First-half 2019 financial report (in French)
Précédent
1
2